HIV Dynamics and Replication Program
About Our Program
The HIV Dynamics and Replication Program (HIV DRP) was formed in 1997 as the HIV Drug Resistance Program, with the mission of conducting and fostering multidisciplinary basic, translational, and clinical research focused on problems related to drug-resistant HIV.
The scope of research conducted by HIV DRP scientists has expanded over the years to encompass a broader range of important problems in virus biology. Thus, in 2015, the name of the Program was changed to HIV Dynamics and Replication to better capture the breadth of the research carried out by the Program. Read more...
- Integrase strand transfer inhibitors are effective anti-HIV drugs
- Development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CLpro inhibitors
- Efficient HIV-1 in vitro reverse transcription: optimal capsid stability is required
- Mechanistic analysis of the broad antiretroviral resistance conferred by HIV-1 envelope glycoprotein mutations
- Oncogenic HPV promotes the expression of the long noncoding RNA lnc-FANCI-2 through E7 and YY1
- Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants
- Specific guanosines in the HIV-2 leader RNA are essential for efficient viral genome packaging
- PSGL-1 Inhibits the incorporation of SARS-CoV and SARS-CoV-2 spike glycoproteins into pseudovirions and impairs pseudovirus attachment and infectivity
- Opposing activities of IFITM proteins in SARS-CoV-2 infection
- Structural mimicry drives HIV-1 Rev-mediated HERV-K expression
- How to package the RNA of HIV-1
- Impact of nuclear export pathway on cytoplasmic HIV-1 RNA transport mechanism and distribution